Edgewood is a clinical-stage, venture funded oncology company developing a set of related assets targeting a novel, soluble checkpoint molecule in the tumor microenvironment. The mechanism of action uniquely activates both NK cell and antigen-experienced T cells promoting both innate and adaptive immunity. The company's clinical stage asset, EDG-100, is cleared for clinical trials in combination with PD-1s. A bispecific antibody development candidate EDG-200, is now entering preclinical development. And a third asset, EDG-300, has been specifically designed to enhance CAR-T therapy and has reached preclinical proof-of-concept stage.